Wharton’s Jelly-Derived Mesenchymal Stromal Cells as a Promising Cellular Therapeutic Strategy for the Management of Graft-versus-Host Disease

摘要: Allogeneic hematopoietic cell transplantation (allo-HCT), a treatment option in hematologic malignancies and bone marrow failure syndromes, is frequently complicated by Graft-versus-host disease (GVHD). The primary for GVHD involves immune suppression glucocorticoids. However, patients are often refractory to the steroid therapy, this results poor prognosis. Therefore alternative therapies needed treat GVHD. Here, we review data supporting clinical investigation of novel cellular therapy using Wharton’s jelly (WJ)-derived mesenchymal stromal cells (MSCs) as potentially safe effective therapeutic strategy management Adult-derived sources MSCs have demonstrated signals efficacy there limitations, including: limited proliferation capacity; heterogeneity sources; lengthy expansion time dose; vitro; painful, invasive, isolation procedure donor. Therefore, MSC sought. reviewed suggests derived from WJ may be Laboratories investigated defined properties WJ-MSCs potential use therapy. These represent more uniform population than marrow-derived MSCs, displaying robust immunosuppressive lacking significant immunogenicity. They can collected safely painlessly individuals at birth, rapidly expanded stored cryogenically later use. Additionally, suggested licensing (activating exposure cytokines) enhance effectiveness treating WJCs should tested second generation, relatively homogeneous allogeneic